Engineered artificial antigen presenting cells enhance tumor-infiltrating lymphocyte expansion
Author Information
Author(s): Ye Qunrui, Loisiou Maria, Levine Bruce L, Suhoski Megan M, Riley James L, June Carl H, Coukos George, Powell Daniel J Jr
Primary Institution: Perelman School of Medicine, University of Pennsylvania
Hypothesis
Can genetically-engineered artificial antigen presenting cells (aAPCs) facilitate the rapid expansion of tumor-infiltrating lymphocytes (TILs) for adoptive immunotherapy?
Conclusion
Genetically-enhanced aAPCs provide a standardized platform for the efficient expansion of TILs suitable for adoptive immunotherapy.
Supporting Evidence
- TILs expanded using aAPCs showed a favorable CD4/CD8 T cell ratio.
- aAPCs allowed for the rapid expansion of TILs directly from fresh tumor specimens.
- TILs expanded with aAPCs maintained tumor-reactivity and specific T cell characteristics.
- The aAPC platform reduced the need for allogeneic feeder cells, simplifying the expansion process.
Takeaway
Scientists created special cells that help grow cancer-fighting immune cells faster, making it easier to treat cancer patients.
Methodology
The study used genetically-engineered K562 cell-based aAPCs to stimulate and expand TILs from cancer specimens in the presence of IL-2.
Limitations
The study primarily focused on TILs from ovarian cancer and melanoma, which may limit the generalizability of the findings to other cancer types.
Participant Demographics
Patients with ovarian cancer and melanoma were included for TIL extraction.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website